IRIDEX CORPORATION (NASDAQ:IRIX) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03.
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On March 27, 2019, the Board of Directors of Iridex Corporation (the “Company”) amended and restated the Company’s bylaws (as so amended and restated, the “Bylaws”). Among other things, the amendments to the Bylaws:
|
provide that the chairman of any stockholder meeting has the power to adjourn the meeting; |
|
clarify the requirements for stockholders to nominate directors or bring other business before an annual or special meeting of stockholders, including adjusting the dates on which director nominations or proposals of other business must be received by the Company in order to be in compliance with the Bylaws; |
|
clarify certain of the requirements related to stockholders acting by written consent; and |
|
make certain other language and conforming changes and other technical edits and updates. |
The amendments to the Bylaws did alter the advance notice period for director nominations or proposals of business at the Company’s 2019 Annual Meeting of Stockholders.
The foregoing description of the amendments to the Bylaws is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
|
Item 9.01. |
Financial Statements and Exhibits. |
IRIDEX CORP Exhibit
EX-3.1 2 irix-ex31_7.htm EX-3.1 irix-ex31_7.htm Exhibit 3.1 AMENDED AND RESTATED BYLAWSOFIRIDEX CORPORATION TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS 1.1 ANNUAL MEETINGS 1 1.2 SPECIAL MEETINGS 1 1.3 NOTICE OF MEETINGS 1 1.4 ADVANCE NOTICE OF STOCKHOLDER NOMINEES AND STOCKHOLDER BUSINESS 2 1.5 ADJOURNMENTS 6 1.6 QUORUM 7 1.7 ORGANIZATION 7 1.8 VOTING; PROXIES 7 1.9 FIXING DATE FOR DETERMINATION OF STOCKHOLDERS OF RECORD 8 1.10 LIST OF STOCKHOLDERS ENTITLED TO VOTE 9 1.11 ACTION BY CONSENT OF STOCKHOLDERS 10 ARTICLE II BOARD OF DIRECTORS 13 2.1 NUMBER; QUALIFICATIONS 13 2.2 ELECTION; RESIGNATION; REMOVAL; VACANCIES 13 2.3 REGULAR MEETINGS 13 2.4 SPECIAL MEETINGS 14 2.5 TELEPHONIC MEETINGS PERMITTED 14 2.6 QUORUM; VOTE REQUIRED FOR ACTION 14 2.7 ORGANIZATION 15 2.8 BOARD ACTION BY WRITTEN CONSENT WITHOUT A MEETING 15 ARTICLE III COMMITTEES 15 3.1 COMMITTEES 15 3.2 COMMITTEE RULES 16 ARTICLE IV OFFICERS 16 4.1 EXECUTIVE OFFICERS; ELECTION; QUALIFICATIONS; TERM OF OFFICE; RESIGNATION; REMOVAL; VACANCIES 16 4.2 POWERS AND DUTIES OF EXECUTIVE OFFICERS 16 ARTICLE V STOCK 17 5.1 STOCK CERTIFICATES 17 5.2 LOST,…
To view the full exhibit click here
About IRIDEX CORPORATION (NASDAQ:IRIX)
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.
